JULIAN BAKER
CIK 1087939 · last filed 2026-06-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$4.41B
Companies
38
Total Filings
402
Lifetime Open-Market Net
$3.10B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ONC | Director | 161,551 | $262.68 | $42.44M | $0 | 1 | 2026-06-15 |
| PRLD | Director | — | $4.35 | — | $0 | 3 | 2026-06-10 |
| INCY | Director | 28,469,908 | $98.99 | $2.82B | $1.09B | 78 | 2026-04-02 |
| TRDA | 10%+ Owner | 381,338 | $6.81 | $2.60M | $1.05M | 2 | 2025-11-24 |
| IGM Biosciences, Inc. (IGMS) Delisted | Director | 357,048 | $1.27 | $453.5K | $20.55M | 8 | 2025-07-02 |
| KYMR | Director | — | $89.90 | — | $0 | 1 | 2025-06-26 |
| KNSA | Director | 2,753,656 | $54.21 | $149.28M | $0 | 3 | 2025-06-05 |
| DNLI | Director | 3,415,958 | $23.49 | $80.24M | $0 | 1 | 2025-06-05 |
| BCYC | Director | 918,483 | $4.04 | $3.71M | $0 | 2 | 2025-01-06 |
| KALA | 10%+ Owner | 118,496 | $2.85 | $337.1K | $8.00M | 1 | 2024-12-31 |
| Talis Biomedical Corp (TLIS) Delisted | Director | — | $2.84 | — | $0 | 1 | 2022-06-13 |
| ACAD | Director | 3,609,489 | $21.60 | $77.96M | $0 | 8 | 2022-06-09 |
| KOD | Director | 15,604,214 | $35.71 | $557.23M | $568.05M | 4 | 2022-06-06 |
| TCRX | Director | — | $0.90 | — | $0 | 1 | 2022-06-03 |
| Neurogene Inc. (NLTX) Delisted | Director | — | $13.96 | — | $0 | 2 | 2022-05-16 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 1 | 2021-02-25 |
| Atreca, Inc. (BCEL) Delisted | 10%+ Owner | 309,730 | $0.15 | $46.5K | $0 | 2 | 2020-07-20 |
| BeOne Medicines Ltd. (BGNE) Delisted | Director | 5,293,600 | $184.71 | $977.78M | $321.33M | 4 | 2020-06-19 |
| Seagen Inc. (SGEN) Delisted | Director | 46,041,889 | $228.74 | $10.53B | $1.10B | 32 | 2020-04-24 |
| ZYME | Director | — | $23.14 | — | $0 | 1 | 2020-03-16 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 1,216,909 | — | — | -$101.91M | 69 | 2019-08-30 |
| Aceragen, Inc. (IDRA) Delisted | Director | 21,929 | $7.22 | $158.4K | -$13.97M | 22 | 2019-06-07 |
| BELLICUM PHARMACEUTICALS, INC (BLCM) Delisted | 10%+ Owner | 58,131 | $0.07 | $4.3K | -$28.88M | 1 | 2018-01-19 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | — | $58.70 | — | $0 | 1 | 2017-11-20 | |
| Invitae Corp (NVTA) Delisted | 10%+ Owner | — | $0.09 | — | $0 | 1 | 2017-08-02 |
| NTLA | 796,683 | $15.20 | $12.11M | $14.40M | 1 | 2016-05-11 | |
| Neurogene Inc. (AQXP) Delisted | 10%+ Owner | 826,628 | — | — | $27.87M | 3 | 2016-03-16 |
| XOMA | Director | 14,832,615 | $41.72 | $618.82M | $33.63M | 4 | 2014-12-30 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | 10%+ Owner | 3,540,015 | — | — | $10.19M | 2 | 2012-03-14 |
| SYNAGEVA BIOPHARMA CORP (GEVA) Delisted | Director | 1,736,065 | — | — | $0 | 4 | 2012-01-09 |
| VIROPHARMA INC (VPHM) Delisted | 10%+ Owner | 303,264 | — | — | -$6.20M | 24 | 2011-12-16 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | 126,709 | — | — | $52.46M | 11 | 2011-07-05 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | 10%+ Owner | 6,992 | — | — | $81.52M | 5 | 2011-03-31 |
| RPRX | 10%+ Owner | 179,881 | $53.70 | $9.66M | $1.22M | 4 | 2010-06-02 |
| NEUROGEN CORP (NRGN) Delisted | Director | 3,500,059 | — | — | $0 | 18 | 2009-12-17 |
| BCRX | 10%+ Owner | 4,090,786 | $8.95 | $36.61M | -$9.19M | 4 | 2009-06-01 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | 10%+ Owner | 2,022,293 | — | — | -$69.50M | 26 | 2009-02-06 |
| Aceragen, Inc. (IDP) Delisted | 10%+ Owner | 550,546 | — | — | -$9.23M | 11 | 2007-11-15 |
Recent Filings · Page 38 of 41
402 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2007-05-30 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +1,635 | $26.7K | EDGAR |
| 2007-05-24 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +1,534,659 | $25.46M | EDGAR |
| 2007-05-24 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +581,898 | $9.65M | EDGAR |
| 2007-05-24 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +3,909 | $64.9K | EDGAR |
| 2007-05-22 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +3 | $46 | EDGAR |
| 2007-05-22 | INCY | Grant (A) | — | $0 | EDGAR |
| 2007-05-22 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +5,409 | $83.8K | EDGAR |
| 2007-04-17 | VIROPHARMA INC (VPHM) Delisted | Sell (S) | −1,633,656 | -$25.09M | EDGAR |
| 2007-03-15 | NEUROGEN CORP (NRGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-03-13 | GENOMIC HEALTH INC (GHDX) Delisted | Buy (P) | +16,125 | $294.8K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.